RESUMEN
Granulomatous Mastitis (GM) is a rare chronic inflammatory lesion of the breast that clinically simulate carcinoma. The purpose of this report is to review the clinicopathological features of this clinical entity in a series of 5 cases that were diagnosed at our institute. Mammography, ultrasonography, and fine needle aspiration were performed in all cases. The treatment of choice for granulomatous mastitis is unclear. Of the 5 cases, one case underwent steroid therapy, two cases underwent anti-tuberculosis medication, and the others underwent only excision. There were no complications for the 5 cases during the follow-up periods. Therefore, the diagnosis and treatment of granulomatous mastitis should be determined on a case by case basis, by the clinician considering the various case results that have been reported on.
Asunto(s)
Biopsia con Aguja Fina , Mama , Diagnóstico , Estudios de Seguimiento , Mastitis Granulomatosa , Mamografía , UltrasonografíaRESUMEN
PURPOSE: Fatty acid synthase (FAS) is a multi-enzyme molecule that plays a role in the de novo biosynthesis of fatty acids. FAS is expressed at low levels in most normal human tissues because, cells preferentially utilize circulating lipids for the synthesis of new structural lipids. Recent studies have demonstrated that high levels of FAS occur in a subset of human cancers (such as breast, ovary, and prostate cancer etc) and these high FAS levels are associated with a poor prognosis. The aim of this study was to investigate the expression of FAS in breast cancer and to examine the relationship between FAS and the clinicopathological data. METHODS: We reviewed clinical profiles [clinical data and short term outcome (recurrence)] of 67 breast cancer patients by reviewing their medical records. The average followed-up period was 22.6 month. FAS expressions were evaluated by immunohistochemistry on the formalin-fixed paraffin-embedded tissues. RESULTS: FAS expression of breast cancer was nonspecifically high, but there was no statistical importance between the FAS expression, the clinicopathological data and the short term recurrence (p > 0.05). CONCLUSION: The overexpression of FAS in breast cancer patients may not be a reliable marker for a poor prognosis. However, further studies are required in order to define the biological significance and the specific role of FAS in breast cancer development, growth, and invasion. Also, inhibition of FAS may be a target treatment for breast cancer.
Asunto(s)
Femenino , Humanos , Neoplasias de la Mama , Mama , Ácidos Grasos , Inmunohistoquímica , Registros Médicos , Ovario , Pronóstico , Neoplasias de la Próstata , RecurrenciaRESUMEN
PURPOSE: Fatty acid synthase (FAS) is a multi-enzyme molecule that plays a role in the de novo biosynthesis of fatty acids. FAS is expressed at low levels in most normal human tissues because, cells preferentially utilize circulating lipids for the synthesis of new structural lipids. Recent studies have demonstrated that high levels of FAS occur in a subset of human cancers (such as breast, ovary, and prostate cancer etc) and these high FAS levels are associated with a poor prognosis. The aim of this study was to investigate the expression of FAS in breast cancer and to examine the relationship between FAS and the clinicopathological data. METHODS: We reviewed clinical profiles [clinical data and short term outcome (recurrence)] of 67 breast cancer patients by reviewing their medical records. The average followed-up period was 22.6 month. FAS expressions were evaluated by immunohistochemistry on the formalin-fixed paraffin-embedded tissues. RESULTS: FAS expression of breast cancer was nonspecifically high, but there was no statistical importance between the FAS expression, the clinicopathological data and the short term recurrence (p > 0.05). CONCLUSION: The overexpression of FAS in breast cancer patients may not be a reliable marker for a poor prognosis. However, further studies are required in order to define the biological significance and the specific role of FAS in breast cancer development, growth, and invasion. Also, inhibition of FAS may be a target treatment for breast cancer.